As demonstrated by the herein reviewed large variety of 18F-labeled radiotracers, recent years have witnessed a tough competition in PSMA inhibitor imaging, which may be mainly driven by the ease of radiochemistry and the high incidence of PCa compared to other gender-specific tumor entities. This evidence concerns the gene FOLH1 and posterior cortical atrophy.